IS2463B - Útskipt díketópíperasín og notkun þeirra sem oxytósínmótlyfja - Google Patents

Útskipt díketópíperasín og notkun þeirra sem oxytósínmótlyfja

Info

Publication number
IS2463B
IS2463B IS8248A IS8248A IS2463B IS 2463 B IS2463 B IS 2463B IS 8248 A IS8248 A IS 8248A IS 8248 A IS8248 A IS 8248A IS 2463 B IS2463 B IS 2463B
Authority
IS
Iceland
Prior art keywords
diketopiperazine
substitution
oxytocin antagonists
oxytocin
antagonists
Prior art date
Application number
IS8248A
Other languages
English (en)
Other versions
IS8248A (is
Inventor
Liddle John
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS8248A publication Critical patent/IS8248A/is
Publication of IS2463B publication Critical patent/IS2463B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IS8248A 2003-06-24 2006-01-20 Útskipt díketópíperasín og notkun þeirra sem oxytósínmótlyfja IS2463B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0314738A GB0314738D0 (en) 2003-06-24 2003-06-24 Novel compounds
PCT/EP2004/006814 WO2005000840A1 (en) 2003-06-24 2004-06-22 Substituted diketopiperazines and their use as oxytocin antagonists

Publications (2)

Publication Number Publication Date
IS8248A IS8248A (is) 2006-01-20
IS2463B true IS2463B (is) 2008-11-15

Family

ID=27637257

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8248A IS2463B (is) 2003-06-24 2006-01-20 Útskipt díketópíperasín og notkun þeirra sem oxytósínmótlyfja

Country Status (30)

Country Link
US (6) US8071594B2 (is)
EP (1) EP1641787B1 (is)
JP (1) JP5128126B2 (is)
KR (1) KR101131378B1 (is)
CN (2) CN101597282A (is)
AR (1) AR044869A1 (is)
AT (1) ATE361295T1 (is)
AU (1) AU2004251868B2 (is)
BR (1) BRPI0411729A (is)
CA (1) CA2530310C (is)
CY (1) CY1107703T1 (is)
DE (1) DE602004006268T2 (is)
DK (1) DK1641787T3 (is)
EG (1) EG24929A (is)
ES (1) ES2285474T3 (is)
GB (1) GB0314738D0 (is)
HR (1) HRP20070286T3 (is)
IL (1) IL172529A (is)
IS (1) IS2463B (is)
MA (1) MA27887A1 (is)
MX (1) MXPA05014068A (is)
MY (1) MY140653A (is)
NO (1) NO332677B1 (is)
NZ (1) NZ544006A (is)
PL (1) PL1641787T3 (is)
PT (1) PT1641787E (is)
RU (1) RU2343152C2 (is)
TW (1) TWI340745B (is)
WO (1) WO2005000840A1 (is)
ZA (1) ZA200509890B (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130677D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
GB0314738D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0414100D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
EP2493874A1 (en) 2009-10-30 2012-09-05 Glaxo Group Limited Novel crystalline forms of (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - dimethyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoethyl]-6- [(1s) - 1 -methylpropyl]-2,5- piperazinedione
AU2014397706A1 (en) 2014-06-16 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Retosiban for the treatment of pre-term labour
LT3400217T (lt) 2016-01-04 2022-06-27 Merck Serono S.A. Hidroksipropiltiazolidino karboksamido l-valinato darinys, jo druska ir jo kristalinė forma
WO2018015497A2 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CN106674031A (zh) * 2016-11-18 2017-05-17 浙江工业大学 R‑2‑二氢茚氨酸的制备方法
AU2020340670A1 (en) 2019-09-03 2022-04-07 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
WO2021160597A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596819A (en) 1984-01-23 1986-06-24 Warner-Lambert Company Modified tripeptides
US5091387A (en) * 1990-03-02 1992-02-25 Merck & Co., Inc. Spirocyclic oxytocin antagonists
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5817751A (en) 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
US5968938A (en) * 1997-06-18 1999-10-19 Merck & Co., Inc. Piperazine oxytocin receptor antagonists
GB2326639A (en) * 1997-06-18 1998-12-30 Merck & Co Inc Piperazine Oxytocin Receptor Antagonists
WO1999037304A1 (en) 1998-01-27 1999-07-29 Aventis Pharmaceuticals Products Inc. SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
HUP0101329A3 (en) 1998-01-29 2002-07-29 Aventis Pharmaceuticals Inc Co Method for preparing an n-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compounds and a cyclyzed compounds there from
CA2289621A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (fbpase)
GB2372740A (en) 2001-01-17 2002-09-04 Xenova Ltd Diketopiperazines
GB0130677D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
US20030229001A1 (en) 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
GB0314738D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0314733D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
GB0414100D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414092D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
CN103930132A (zh) 2011-09-27 2014-07-16 拜奥迈德瓦利探索有限公司 治疗胶质瘤的组合物和方法

Also Published As

Publication number Publication date
AR044869A1 (es) 2005-10-05
NO20060383L (no) 2006-01-24
HK1088910A1 (en) 2006-11-17
WO2005000840A1 (en) 2005-01-06
ZA200509890B (en) 2006-07-26
US20150105387A1 (en) 2015-04-16
CY1107703T1 (el) 2013-04-18
US20160074413A1 (en) 2016-03-17
IS8248A (is) 2006-01-20
US8937179B2 (en) 2015-01-20
EP1641787A1 (en) 2006-04-05
JP2009513484A (ja) 2009-04-02
AU2004251868A1 (en) 2005-01-06
US20130102783A1 (en) 2013-04-25
CN1812987A (zh) 2006-08-02
DE602004006268D1 (de) 2007-06-14
RU2343152C2 (ru) 2009-01-10
CN100404532C (zh) 2008-07-23
CA2530310C (en) 2012-01-03
US8357685B2 (en) 2013-01-22
EP1641787B1 (en) 2007-05-02
DE602004006268T2 (de) 2008-01-10
CN101597282A (zh) 2009-12-09
US8071594B2 (en) 2011-12-06
KR20060024440A (ko) 2006-03-16
WO2005000840A8 (en) 2005-05-19
US20120004229A1 (en) 2012-01-05
US9452169B2 (en) 2016-09-27
RU2006101859A (ru) 2006-06-10
AU2004251868B2 (en) 2009-01-22
HRP20070286T3 (en) 2007-08-31
CA2530310A1 (en) 2005-01-06
DK1641787T3 (da) 2007-09-17
MXPA05014068A (es) 2006-03-02
US20070149524A1 (en) 2007-06-28
NZ544006A (en) 2008-12-24
EG24929A (en) 2011-01-05
US20140058105A1 (en) 2014-02-27
KR101131378B1 (ko) 2012-04-04
PT1641787E (pt) 2007-08-01
BRPI0411729A (pt) 2006-08-08
JP5128126B2 (ja) 2013-01-23
IL172529A0 (en) 2006-04-10
MA27887A1 (fr) 2006-05-02
PL1641787T3 (pl) 2007-08-31
ES2285474T3 (es) 2007-11-16
IL172529A (en) 2011-06-30
GB0314738D0 (en) 2003-07-30
TWI340745B (en) 2011-04-21
MY140653A (en) 2010-01-15
ATE361295T1 (de) 2007-05-15
TW200524917A (en) 2005-08-01
NO332677B1 (no) 2012-12-03

Similar Documents

Publication Publication Date Title
NL350092I2 (nl) Combinatie van bixafen en fluoxastrobine
IS7620A (is) Qínólín afleiður og notkun þeirra sem tálma sveppagerla
IL172471A0 (en) Gsk-3 inhibitors and uses thereof
IS7926A (is) 4-útskipt bensímídasól og notkun þeirra sem magasýruseytishemla
NL1029596A1 (nl) Nieuwe piperidylderivaten van chinazoline en isochinoline.
IS7700A (is) Ný spíróþétt kínasólínón og notkun þeirra sem fosfórdíesterasa hindrar
EP1572103A4 (en) ANTI-ANGIOGENIC USES OF IL-6 ANTAGONISTS
JP2006502186A5 (ja) β-グルカンの使用
IL172467A0 (en) Quinolyl amide derivatives as ccr-5 antagonists
IL169336A0 (en) Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
DK1513531T3 (da) Basisk non-peptide bradykinin antagonister og farmaceutiske sammensætninger deraf
IS2463B (is) Útskipt díketópíperasín og notkun þeirra sem oxytósínmótlyfja
ATE356124T1 (de) Hydroxyalkylsubstituierte pyrido-7-pyrimidin-7- one
AU2003277215A8 (en) Novel neurokinin antagonists and methods of use thereof
EP1670739A4 (en) CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS
DK1799214T3 (da) Ikke-peptid-bradykinin-antagonister og famaceutiske sammensætninger heraf
ZA200606070B (en) Substituted quinolines and their use as mycrobacterial inhibitors
PL379702A1 (pl) Pochodne benzamidu jako agoniści oksytocyny i antagoniści wazopresyny
PL377898A1 (pl) 3-fenylo-3-podstawione 4-ketolaktamy i 4-ketolaktony
IL169337A0 (en) Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
DE602004024640D1 (de) Reinigung von titantetrachlorid
PL376607A1 (pl) Zastosowanie antagonistów oksytocyny i/lub wazopresyny
SE0300730D0 (sv) New Landmarks and Use Thereof
SE0301366D0 (sv) Rökrum
UA9216S (uk) Комплект патерлиць і хреста